Omeprazol Krka (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Krka, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Omeprazol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens (as adjunct): enhances eradication success when combined with antibiotics. - NSA‑ID‑associated ulcer prophylaxis: lowers risk of ulcer development in high‑risk patients.

Omeprazole is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Abdominal pain or discomfort: occasional. - Nausea or vomiting: may occur early in therapy. - Flatulence: mild bloating. - Constipation: infrequent.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: renal inflammation. - Hypomagnesemia: low serum magnesium levels. - Fracture risk: possible decrease in bone mineral density with long‑term use. - Stevens‑Johnson syndrome/TEN: rare severe skin reactions. - Hepatotoxicity: elevated liver enzymes or hepatitis.

Before initiating Omeprazole, consider patient‑specific factors and monitoring requirements.

- Assess renal and hepatic function: adjust use if impairment is present. - Review concomitant medications: potential for altered absorption or metabolism. - Use the lowest effective dose: limit duration to the shortest necessary period. - Monitor for vitamin B12 deficiency: long‑term therapy may impair absorption. - Evaluate bone health: consider calcium and vitamin D supplementation if therapy exceeds 12 months. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atorvastatin: increased plasma concentrations, heightened risk of myopathy. - Warfarin: enhanced anticoagulant effect, monitor INR closely.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, watch for toxicity signs. - Methotrexate: reduced renal clearance, risk of accumulation. - HIV protease inhibitors (e.g., ritonavir): altered exposure, adjust dosing as needed.